As chief executive, he steered online fashion portal Myntra into a $300 million-acquisition by the e-commerce company Flipkart. Today, the well-dressed and well-coiffed Mukesh Bansal moves away from the business of looking good to the business of feeling great—health platform Cure.fit.

Bansal is a man with an ambitious project that’s reaping quick benefits. Cure.fit raised $43 million in just one year, and now, it has a five-year plan of massive scale up with eyes firmly fixed on the urban middle class and corporate India.

Interestingly, Bansal’s greatest challenge is his antipode, yoga guru-turned-businessman Baba Ramdev. Separated by a decade in age, the two represent divergent outlooks to health, wellness and lifestyle. But they are not so far removed from each other in their end goals.

Through Cure.fit Bansal wants to capitalise on the current wave of what Ramdev’s Patanjali has come to symbolise.  “We want Cure.fit to stand for trust, sort of like Patanjali. Patanjali comes from yoga and spiritual angle, we are coming from a science and youth perspective,” he says. “Ultimately the goal is the same—to build a brand you can trust.”

Before you question the similarity, Bansal is quick to add that Patanjali has a ‘health’ positioning in the products it retails, yoga regimens it promotes, or Ayurveda clinics it runs in some cities. Though it’s another matter that there’s a difference between health positioning and actually delivering health to the customer.

A full stack health platform, with a mix of services and products sold through an app, and a full range branding with .fit, Bansal has the stacks sorted: Offline gyms for fitness in Cult.fit; meditation and yoga centres in Mind.fit; and hyperlocal health-food service in Eat.fit. And by early 2018, it even wants to get into primary healthcare, with Care.fit centres.

Each of these is a complex business. But Bansal is on a tear. Buying gyms, yoga centres and food delivery companies and rebranding them, even though he says “acquisition is not a big part of his strategy”. Cure.fit has acquired six companies in a year.

“We are building 90% of the business ourselves. We have targeted very small companies which can speed up our go-to-market by three to six months. We acquired Cult and Tribe for the teams running them,” he says. He’d like people to know that this time around he is not building a business for vanity metrics, rather a gross profitable business from the start.

Making money

Cure.fit does not monetise the services on its app as on date. It is treated as a customer acquisition channel to bring in sign-ups at its Cult.fit and Mind.fit outlets.

How does Bansal plan to do that given that most digital health companies, even globally, are chipping away on the fringes with no profitability or scale in sight?

AUTHOR

Payal Ganguly

Payal started writing news features six years ago and has written on startups, civic issues and education. Currently based out of Bengaluru, she has worked with The New Indian Express in Hyderabad and more recently, at The Economic Times, writing on e-commerce and logistics. A post-graduate in Molecular Biology and Biochemistry, she will be writing on e-commerce, science and technology at The Ken. She firmly believes that Bollywood classics have the power to heal and inspire.

View Full Profile

Subscribe to read this story

The Ken is the only business subscription you need. Questions?

 

Premium

  • 5 original and reported longform business stories every week
  • Access to ONLY India edition
  • Close to 250 exclusive stories every year
  • Full access to over 5 years of paywalled stories
  • Pick up to 5 premium subscriber newsletters
  • 4 original and reported longform business stories each week
  • Access to ONLY Southeast Asia edition
  • Close to 200 exclusive stories every year
  • Full access to all paywalled stories since March 2020
  • Pick up to 5 premium subscriber newsletters

Rs. 2,750 /year

$ 120 /year

India Edition
Subscribe Subscribe
Most Asked For

Borderless

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories

Rs. 4,200 /year

Subscribe
 

Echelon

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories
  • Bonus annual gift subscription
  • Priority access to all new products and features

Rs. 8,474 /year

Subscribe
Or

Questions?

What kind of subscription plans do you offer?

We have three types of subscriptions
- Premium which gives you access to either the India or the Southeast Asia edition.
- Borderless which gives you complete access to The Ken across both editions
- Echelon which gives you complete access to The Ken across both editions along with a bonus gift subscription

What do I get if I subscribe?

The Premium edition gives you access to stories in that edition along with any five subscriber-only newsletters of your choice.

The Borderless and Echelon subscription gives you complete access to The Ken across editions and unlimited access to as many newsletters as you like.

What topics do you usually write about?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics. We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

Our specialised subscriber-only newsletters are written by our expert, award-winning journalists and cover a range of topics across finance, retail, clean energy, cryptocurrency, ed-tech and many more.

How many newsletters do you have?

We are constantly adding specialised subscriber-only newsletters all the time. All of these are written by our team of award-winning journalists on a specialised topic.

You can see the list of newsletters that we publish over here.

Does a Premium subscription to your Indian edition get me access to the Southeast Asia edition? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

We recommend the Borderless or the Echelon Plan which will give you access to stories across both editions.

Do you have a mobile app?

Yes! We have a top-rated mobile app on both iOS and Android which allows you to read on-the-go and has some amazing features like the ability to bookmark stories, save on your device, dark mode, and much more. It’s really the best way to read The Ken.

Is there a free trial?

You can sign up for a free account to experience The Ken and understand our products better. We’ll send you some free stories and newsletters occasionally, and you can access our archive of previously published free stories. You can stay on the free account as long as you’d like.

The vast majority of our stories, articles and newsletters can be accessed only by a paid subscription.

Do you offer any discounts?

Sorry, no. Our journalism is funded completely by our subscribers. We believe that quality journalism comes at a price, and readers trust and pay us so that we can remain independent.

Do you offer refunds?

No. We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Just write to us at support@the-ken.com with details. We’ll help you out.

I have a few more questions. How can I reach out to you?

Sure. Just email us at info@the-ken.com or follow us on Twitter.